ID BIOMEDICAL'S CYCLING PROBE TECHNOLOGY DNA TESTS FOR DRUG-RESISTANT BACTERIA SLATED FOR LAUNCH IN 1997; POINT-OF-CARE CPT TESTS ALSO PLANNED
This article was originally published in The Gray Sheet
Executive Summary
ID Biomedical's Cycling Probe Technology DNA-based tests for detection of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) could be launched in the U.S. in 1997 following review and approval by FDA, the company predicts. Discussing the two tests Aug. 12 at the Medical Investments Northwest conference in Seattle, ID President and CEO Frank Holler said: "We expect to be able to bring [the tests] to the market next year."
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.